Impact of 4HPR on the expression of E-Cad in human bladder transitional epithelial cancer cells T24

Abstract

Previous researches showed that the expression level of E-Cad in most infiltrating cancer cells was reduced or negative. This study explored whether 4HPR restrained the infiltration of bladder cancer cells through regulating the expression of E-Cad. The infiltrating bladder cancer cells T24 were cultured, and then treated by a proper dosage of drug. Their viability was a determined by MTT method. Western blotting and RT-PCR were adopted to detect the changes of E-Cad gene expression at both protein and mRNA levels. Moreover, immunofluorescent staining and confocal fluorescence microscopy were employed for the observation of the expression of E-Cad. The result showed that, at both mRNA and protein levels, the expression level of E-Cad in T24 cells treated by 4HPR was significantly higher than that of control group, while the β-Cat expression was also relocated from the cell nucleus to cytoplasm. Our findings suggested that the regulatory function of 4HPR on infiltration of bladder cancer cells T24 is at least partly achieved by regulating the expression of E-Cad.

Keywords

4HPR / T24 cells / infiltration / E-Cad

References

[1] SabichiA.L., LernerS.P., GrossmanH.B., et al.. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol, 1998, 10(5): 479-484

[2] Millán-RodríguezF., Chéchile-TonioloG., Salvador-BayarriJ., et al.. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol, 2000, 163(1): 73-78

[3] RosenbergJ.E., CarrollP.R., SmallE.J.. Update on chemotherapy for advanced bladder cancer. J Urol, 2005, 174(1): 14-20

[4] CzyzewskaJ., Guzińska-UstymowiczK., UstymowiczM., et al.. The expression of E-cadherin-catenin complex in patients with advanced gastric cancer: role in formation of metastasis. Folia Histochem Cytobiol, 2010, 48(1): 37-45

[5] BringuierP.P., UmbasR., SchaafsmaH.E., et al.. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res, 1993, 53(14): 3241-3245

[6] YangL.J., LiuY.Q., GuB., et al.. Effect of forced E-cadherin expression on adhesion and proliferation of human breast carcinoma cells. Zhonghua Bing Li Xue Za Zhi (Chinese), 2010, 39(12): 842-847

[7] BehrensJ., MareelM.M., Van RoyF.M., et al.. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol, 1989, 108(6): 2435-2447

[8] PaulsonJ.D., OldhamJ.W., PrestonR.F., et al.. Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide. Fundam Appl Toxicol, 1985, 5(1): 144-150

[9] ChiesaF., TradatiN., MarazzaM., et al.. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. J Cell Biochem (Suppl), 1993, 17F: 255-261

[10] FerrariN., MoriniM., PfefferU., et al.. Inhibition of Kaposi’s sarcoma in vivo by fenretinide. Clin Cancer Res, 2003, 9(16Pt1): 6020-6029

[11] GaraventaA., LukschR., Lo PiccoloM.S., et al.. Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res, 2003, 9(6): 2032-2039

[12] KimH.J., ChakravartiN., OridateN., et al.. N-(4-hydroxyphenyl)retinamide-induced apoptosis triggered by reactive oxygen species is mediated by activation of MAPKs in head and neck squamous carcinoma cells. Oncogene, 2006, 25(19): 2785-2794

[13] DavisR.J.. Signal transduction by the JNK group of MAP kinases. Cell, 2000, 103(2): 193-200

[14] WuJ.M., DiPietrantonioA.M., HsiehT.C.. Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis, 2001, 6(5): 377-388

[15] BindelsE.M., VermeyM., De BothN.J., et al.. Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines. Virchows Arch, 2001, 439(4): 552-559

[16] MaoQ., LiY., ZhengX., et al.. Up-regulation of E-cadherin by small activating RNA inhibits cell invasion and migration in 5637 human bladder cancer cells. Biochem Biophys Res Commun, 2008, 375(4): 566-570

[17] CowinP.. Unraveling the cytoplasmic interactions of the cadherin superfamily. Proc Natl Acad Sci USA, 1994, 91(23): 10 759-10 761

[18] SimeoneA.M., TariA.M.. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci, 2004, 61(12): 1475-1484

[19] FormelliF., BaruaA.B., OlsonJ.A.. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J, 1996, 10(9): 1014-1024

[20] CliffordJ.L., MenterD.G., WangM., et al.. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyp henyl)retinamide in F9 embryonal carcinoma cells. Cancer Res, 1999, 59(1): 14-18

[21] AppiertoV., CavadiniE., PergolizziR., et al.. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer, 2001, 84(11): 1528-1534

[22] SabichiA.L., HendricksD.T., BoberM.A., et al.. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst, 1998, 90(8): 597-605

[23] UlukayaE., WoodE.J.. Fenretinide and its relation to cancer. Cancer Treat Rev, 1999, 25(4): 229-235

[24] SuB., MershonS.M., StonerockL.A., et al.. 4-Hydroxyphenylretinamide (4HPR) derivatives regulate aromatase activity and expression in breast cancer cells. J Steroid Biochem Mol Biol, 2008, 109(1–2): 40-46

[25] NelsonW.J., NusseR.. Convergence of Wnt, beta-catenin, and cadherin pathways. Science, 2004, 303(5663): 1483-1487

[26] BatschéE., MuchardtC., BehrensJ., et al.. RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol, 1998, 18(7): 3647-3658

[27] BrewerM., KirkpatrickN.D., WhartonJ.T., et al.. 4-HPR modulates gene expression in ovarian cells. Int J Cancer, 2006, 119(5): 1005-1013

[28] ShishodiaS., GutierrezA.M., LotanR., et al.. N-(4-hydrox yphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through downregulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products. Cancer Res, 2005, 65(20): 9555-9565